The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Authors Li P, Yang X, Feng Y, Wu L, Ma W, Ding G, Wei Y, Sun L
Received 12 February 2018
Accepted for publication 13 May 2018
Published 26 October 2018 Volume 2018:11 Pages 7521—7527
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Professor Jianmin Xu
Ping Li,1 Xuefang Yang,2 Yumiao Feng,1 Lijuan Wu,1 Wei Ma,1 Gaozhong Ding,1 Yun Wei,1 Lan Sun1
1Department of Dermatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Jiangsu 215001, China; 2The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital Eastern, Jiangsu 215001, China
Background: Immunosenescence, the age-related decline of immunity, affects the immune responses of melanoma patients. Through immune responses, immune checkpoint inhibitors (ICIs) exert their antitumor robustness. In different ages of melanoma patients, especially the older patients, the effectiveness of ICIs remains unclear. It is still controversial whether ICIs should be used in treating older patients.
Materials and methods: The authors included clinical trials of ICIs in older and younger patients. The authors used hazard ratio (HR) and 95% CI of overall survival (OS).
Results: From four phase III randomized clinical trials 2,251 melanoma patients were included. We found that ICIs significantly prolonged the OS for melanoma patients in both younger (HR, 0.71; 95% CI, 0.60–0.82; P<0.001) and older groups (HR, 0.62; 95% CI, 0.41–0.83; P<0.001) compared with controls. Anti-programmed death-1 (PD-1) agents appeared to be more efficient in older melanoma patients (HR, 0.34; 95% CI, 0.14–0.53) versus younger patients (HR, 0.52; 95% CI, 0.26–0.78).
Conclusion: ICIs significantly prolonged the OS for melanoma patients in both younger and older groups than controls. Anti-PD-1 agents were more efficient in older melanoma patients versus younger patients. ICIs could be used for older melanoma patients.
Keywords: immunosenescence, aging, immune checkpoint inhibitor, PD-1, melanoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]